Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05065957
Other study ID # Inno-GO-05
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 29, 2022
Est. completion date December 2026

Study information

Verified date March 2024
Source InnoPharmax Inc.
Contact Yuyuan Lin
Phone 886-87977607
Email yuan.lin@innopharmax.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).


Description:

This open label, multicenter study will be conducted in 2 stages: a dose-finding stage (Phase IIa) and a dose-expansion stage (Phase IIb/III). In phase IIa, eligible patients will be assigned to receive oral D07001-softgel on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle (9 doses per cycle) and Xeloda (or TS-1) twice daily on Day 1-14 of a 21-day cycle. A modified 3+3 dose-finding design method will be applied to identify dose-limiting toxicities (DLTs) and establish the selected dose of D07001-softgel capsules plus Xeloda (or TS-1). In phase IIb/III,the first 40 subjects (20 subjects per arm) will be randomly allocated in a 1:1 ratio in two arms. Arm A will receive active symptom control (ASC) with the selected dose from dose-finding stage of D07001-softgel capsules and Xeloda (or TS-1), in 21-day cycles. In arm B, subjects will receive ASC with mFOLFOX treatment. After the last subject of first 40 subjects will be completed the visit in the end of treatment, an adaptive interim analysis will be planned to re-estimate the required sample size based on the result of DCR if needed. The sponsor team will determine whether the study will be continued or stopped for futility. If the study continues to proceed, the total subject number will be based on the decision from the results of interim study. The rest of subjects will be randomized to receive the combination of study drug or active-control drug with the same allocation in two arms. Both groups will continue the therapy until disease progression, withdrawn consent, or when another treatment discontinuation criterion is met.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2026
Est. primary completion date July 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female patients aged 18 years or older at screening (aged 20 years or older in Taiwan) 2. Histopathological or cytologic diagnosis of unresectable metastatic or locally advanced BTC (cholangiocarcinoma, gallbladder cancer or ampullary carcinoma) 3. Subject must have failed from first line gemcitabine and cisplatin-based chemotherapy 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 5. Life expectancy is >12 weeks 6. Adequate bone marrow function, demonstrated by: 1. Absolute neutrophil count (ANC) =1,500 cell/mm3 2. Platelet count = 100,000 cells/mm3 3. Hemoglobin = 9 g/dL 7. Adequate liver function, demonstrated by: 1. Aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 x upper limit of normal (ULN), or =5.0 x ULN in the case of liver metastases 2. Total bilirubin =1.5 x ULN 3. Albumin =3.0 g/dL 4. International normalized ratio (INR) <1.5 8. Adequate renal function, demonstrated by: 1. Serum creatinine =1.5 x ULN 2. Creatinine clearance = 50mL/min calculated by Cockcroft-Gault formula or eGFR = 50mL/min/1.73m2 by 2021 CKD-EPI Creatinine Equation 9. A negative serum pregnancy test at screening and is not breastfeeding in woman of childbearing potential 10. Women of childbearing potential or male subjects must use a medically acceptable form of contraception as 2 barrier methods (e.g., combination of condom, diaphragm, or intrauterine device), hormonal contraception (estrogen or progesterone agents) or 1 barrier method in combination with spermicide. Birth control is required 1 month prior to screening, for the duration of their study participation, and for 1 month after the end of the study; female partners of male subjects must adhere to the same birth control methods. 11. Provision of a signed and dated written Informed Consent Form (ICF) prior to any study specific procedures 12. Subject is willing to comply with protocol-required visit schedule and visit requirements 13. No more than 60 days have elapsed between completion of the prior line of chemotherapy or CCRT and enrollment 14. Subject has not received other chemotherapy since first-line treatment Exclusion Criteria: 1. Have prior chemotherapy regimen other than first line gemcitabine and cisplatin-based therapy for unresectable metastatic or locally advanced BTC Note: prior fluoropyrimidine base (including capecitabine, carmofur (HCFU), doxifluridine, fluorouracil (5-FU), and tegafur) chemotherapy (including fluoropyrimidine monotherapy or combination therapy) are allowed as postsurgical adjuvant therapy. 2. Diagnosis of active malignancy other than BTC within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent 3. Prior discontinuation of gemcitabine because of pulmonary or hepatic toxicity or hemolytic uremic syndrome (HUS) or hypersensitivity, allergic reaction, or intolerance 4. Known or suspected hypersensitivity to capecitabine, tegafur, gimeracil, oteracil potassium, oxaliplatin or other platinum compounds, leucovorin products, folic acid or folinic acid, 5-fluorouracil or their excipients. 5. Prior discontinuation of fluoropyrimidine because of any unexpected or severe reaction. 6. Treatment with brivudine, sorivudine, or its chemically-related analogs = 28 days prior to the date of enrollment. 7. Under flucytosine treatment. 8. Residual toxicity from prior chemotherapy or CCRT that is Grade =2 (residual Grade 2 neuropathy and alopecia are permitted) 9. Any GI disorder which would significantly impede absorption of an oral agent 10. Known brain or leptomeningeal metastases 11. Major surgery or definitive ablation-intent (excluding palliative radiotherapy for bone metastasis) radiation therapy within the past 28 days 12. Any active disease or condition that would not permit compliance with the protocol 13. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association [NYHA] Grade 2 or greater), or uncontrolled serious cardiac arrhythmia 14. Have documented cerebrovascular disease. Subjects with the disease may be excluded, but if the investigator assesses that they are asymptomatic or well controlled could be enrolled. 15. Have a seizure disorder not controlled on medication (based on decision of Investigator) 16. Received an investigational agent within 28 days of enrollment 17. Have an uncontrolled active viral, bacterial, or systemic fungal infection 18. Known human immunodeficiency virus (HIV) infection 19. Have HBsAg (hepatitis B surface antigen) positive with HBV-DNA =2000 copies/ml and/or anti-HCV antibody (HCV) positive with HCV-RNA positive. 20. Received yellow fever vaccine or other live attenuated vaccine(s) within the 4 weeks prior to screening 21. History of drug or alcohol abuse within last year 22. Have any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in, and compliance with, a clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D07001-softgel capsules + Xeloda (or TS-1)
D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle). Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)
mFOLFOX
intravenous infusion on Day 1 for 14-day cycle

Locations

Country Name City State
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung
Taiwan China Medical University Hospital Taichung
Taiwan National Taiwan University Cancer Center Taipei
Taiwan National Taiwan University Hospotal Taipei
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
InnoPharmax Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events (AEs)/ serious adverse event (SAEs) AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 From date of informed consent to 30-day follow-up visit for each subject
Primary To assess disease control rate (DCR) To assess DCR, the percentage of treatment patients who achieved CR, PR, or SD. From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
Secondary Phase IIa and IIb: Pharmacokinetics (PK) of gemcitabine (dFdC), difluorodeoxyuridine (dFdU), capecitabine, 5-FU, Tegafur, Gimeracil, and Oteracil potassium PK parameters (Peak Plasma Concentration (Cmax)) of gemcitabine and Xeloda or TS-1 will be evaluated Cycle 1 Days 1, 8, and 12 (each cycle is 21 days)
Secondary Quality of life (QOL) will be assessed using the EORTC questionnaires To access healthrelated quality of life of cancer patients participating in clinical trial. Cycle 1 Days 1, and date of withdraw the study (assessed up to 24 months) for each subject (each cycle is 21 days)
Secondary To assess Progression-free survival (PFS) To assess PFS, the time from treatment assignment/randomization until objective tumor progression or death From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
Secondary To assess Objective response rate (ORR) To assess ORR, the proportion of treated patients who achieved a BOR of CR or PR. From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months
Secondary To assess overall survival (OS) To assess OS, the time from treatment assignment/randomization until death from any case The survival follow-ups will follow every 6 weeks from date of discontinued study drug for up to 24 months till the death of the subject or closure of the study.
See also
  Status Clinical Trial Phase
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Withdrawn NCT03110510 - FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00380588 - Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase 2
Terminated NCT00090025 - XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Phase 3
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT05998447 - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer Phase 2
Recruiting NCT03718897 - Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
Recruiting NCT05056116 - A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer N/A
Recruiting NCT04692051 - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Recruiting NCT04057365 - Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Recruiting NCT04584996 - CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
Completed NCT02579616 - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy Phase 2
Recruiting NCT05052099 - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT01494363 - Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Phase 2
Completed NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Phase 2
Terminated NCT00630890 - Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) Phase 1
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition